Welcome to our dedicated page for Processa Pharmaceuticals SEC filings (Ticker: PCSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Processa Pharmaceuticals filings document formal 8-K and amended 8-K disclosures for a clinical-stage biopharmaceutical issuer. The records cover material events involving licensing and term-sheet matters, Nasdaq listing compliance, executive-officer status changes and compensatory arrangements, and shareholder-vote reporting.
The company's filings also describe capital-structure and charter actions, including amendments to its certificate of incorporation, authorized-share changes, reverse stock split mechanics, common-stock rights and related governance approvals. These disclosures frame Processa's public-company status, equity structure and corporate governance alongside its development-stage pharmaceutical business.
Processa Pharmaceuticals, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add updated Part III information on governance, executive pay, ownership and auditor fees. The company reports a non-affiliate equity market value of about $8.1 million as of June 30, 2025 and 2,738,998 common shares outstanding as of April 29, 2026.
The amendment details board and committee composition, independence determinations, meeting activity in 2025, and compensation for key executives and directors, including salaries, bonuses and equity awards. It also outlines employment and severance terms, equity plan capacity, major shareholders, related-party arrangements and audit fees for 2024 and 2025.
Processa Pharmaceuticals is changing the role of Dr. Sian Bigora as she moves toward retirement. Effective May 1, 2026, she will shift from a full-time executive officer position to a part-time employee role but will retain her title of Chief Development and Regulatory Officer.
After this change, she will no longer be treated as an “executive officer” under Section 16 of the Exchange Act, yet she will continue providing services in a reduced capacity. Her current employment agreement will end and be replaced with a new part-time arrangement, while she keeps previously granted equity awards and remains eligible for any prior bonus awards under their original terms.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng reported an open-market purchase of common stock. On April 15, 2026, he bought 1,843 shares of Processa common stock at $2.97 per share, bringing his directly held stake to 3,979 shares.
The filing also shows indirect holdings of 800 shares held through the Ng Cha Family Trust and 3,488 shares held through an account identified as George Ng IRRA FOB George Ng. These lines reflect ownership positions rather than new transactions.
Processa Pharmaceuticals, Inc. director and Chief Executive Officer George K. Ng reported an open-market purchase of 2,136 shares of common stock at $2.535 per share. After this transaction, he directly holds 2,136 shares. He also reports indirect ownership of 800 shares through the Ng Cha Family Trust and 3,488 shares through an account labeled George Ng IRRA FOB George Ng.
Processa Pharmaceuticals director and Pres. Research & Development David Young reported an open-market purchase of 1,545 shares of common stock at $2.97 per share on April 15, 2026. After this trade, he holds 12,107 shares directly, plus indirect holdings of 1,242 shares via the Young-Plaisance Revocable Trust, 432 shares via family entities, and 742 shares via CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Executive Officer George K. Ng bought additional company stock in the open market. He purchased 1,843 shares of common stock at $2.97 per share, bringing his directly held position to 5,492 shares. The filing also lists indirect holdings of 3,488 shares held under "George Ng IRRA FOB George Ng" and 800 shares held through the "Ng Cha Family Trust," showing both personal and related-entity ownership of Processa common stock.
Processa Pharmaceuticals, Inc. Chief Business - Strategy Officer Patrick Lin bought common stock in the open market. On April 15, 2026, he purchased 1,369 shares of Processa common stock at $2.97 per share. After this transaction, he directly holds 4,725 shares and indirectly holds 1,740 shares through the Lin Family Trust dated February 4, 2024.
Processa Pharmaceuticals Chief Administrative Officer Wendy Guy purchased 1,583 shares of common stock in an open-market transaction at $2.97 per share. After this purchase, she holds 4,693 shares directly and 333 shares indirectly through CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Development Officer Sian Bigora reported an open-market purchase of 1,799 shares of common stock at $2.97 per share on April 15, 2026. Following this trade, Bigora directly holds 5,510 common shares and has indirect ownership of 267 shares through CorLyst, LLC.
Processa Pharmaceuticals, Inc. Chief Financial Officer Russell Skibsted reported an open-market purchase of company shares. On April 15, 2026, he bought 1,984 shares of Common Stock at $2.97 per share in a direct ownership transaction, bringing his directly held stake to 4,308 shares.